India Health Ministry Makes New, More Modest CL Push For Emergencies
This article was originally published in PharmAsia News
India's health ministry has renewed its push for imposing a compulsory license for Bristol-Myers Squibb's Sprycel (dasatinib) drug for chronic myeloid leukemia, with the government holding the license.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.